Recent news on Comtan

Abbott pulls out of developing Orion's Simdax in the USA  -  Apr 26, 2007
Pharma Times (subscription),However, its second-best seller, also for Parkinson's, was Comtess/Comtan (entacapone) which brought in 21.6 million euros, down 2.6%, while Simdax sales

Abbott pulls out of developing Orion's Simdax in the USA  -  26 Apr 2007
Pharma Times (subscription),However, its second-best seller, also for Parkinson's, was Comtess/Comtan (entacapone) which brought in 21.6 million euros, down 2.6%, while Simdax sales

7 Companies Searching to Cure Parkinson's  -  26 Apr 2007
Seeking Alpha,Novartis AG (NVS), a very large Swiss pharmaceutical company, has developed Comtan® (entacapone), a medication for the treatment of Parkinson's Disease.

ORION: Orion Group Interim Report 1-3/2007  -  Apr 25, 2007
Kauppalehti (press release),The combined net sales of Orion's proprietary products for Parkinson's Disease, Stalevo (levodopa, entacapone, carbidopa) and Comtess/Comtan (entacapone)

Medical Edge -- Gold-standard treatment for Parkinson's patients  -  26 Mar 2007
Post-Bulletin,Stalevo is a combination of carbidopa/levodopa and entacapone (Comtan). The latter is an inhibitor of catechol-O-methyltransferase -- another enzyme that

Portion of Orion profits may go towards new Simdax study  -  Feb 7, 2007
Pharma Times (subscription),Its second-best seller, also for Parkinson's, was Comtess/Comtan (entacapone) which brought in 74.7 million euros, up 5.8% on the previous year.

Orion Oyj: Orion group financial review (proforma) 1-12/2006  -  Feb 6, 2007
Kauppalehti (press release),Shipments of Stalevo and Comtan to Novartis, the marketing partner, amounted to EUR 112.1 (78.8) million. They increased by about 42% from the comparative

Orion Oyj: Bulletin of orion corporation financial statements for ...  -  Feb 6, 2007
Kauppalehti (press release),The products for Parkinson’s Disease, ie Stalevo® and Comtess®/Comtan®, contributed EUR 91.0 million, or 31% of the total net sales The consolidated

Orion Selects Medidata Rave(R) as Standard for Electronic Data ...  -  Feb 5, 2007
CNW Telbec (Communiqués de presse),Its biggest selling products are Stalevo(R) and Comtess(R)/Comtan(R), both for Parkinson's Disease, and it is the leader in the animal health market for the

Earlier initiation of enhanced levodopa therapy could provide ...  Oct 31, 2006
Stalevo® and Comtess® / Comtan®, treatments originated by Orion for Parkinson’s Disease, are the largest products by sales in Orion’s portfolio. ... -WebWire (press release), Orion Oyj: Orion group financial review 1-6/2006  Aug 7, 2006
The products for Parkinson’s Disease, ie Stalevo and Comtess/Comtan, contributed EUR 94.9 (71.5) million, or 31% (26%) of the total net sales. ... -Kauppalehti



Orion Oyj: Orion group interim report 1-3/2006  May 8, 2006
The global audited sales of Orion’s Stalevo® and Comtess®/Comtan®, were EUR 296.4 (225.7) million, of which Stalevo accounted for EUR 146.6 (73.2) million ... - Kauppalehti

Former Olympian Doell learns to live with Parkinson's Disease  May 7, 2006
She also takes three pills of Mirapex per day and will soon take two pills of a new medication called Comtan. Down the road, she has other medications to try. ... - Winnipeg Free Press (subscription)

Novartis Q1 net beats expectations on underlying growth ...  Apr 23, 2006
Net sales in Europe were down 7 pct in usd but rose 1 pct in local currencies with strong performances from Diovan, Glivec, Femara, Comtan/Stalevo and Exelon ... - Forbes

(PZ) Novartis Delivers Strong Start to 2006 in First Quarter with ...  Apr 24, 2006
...in Europe declined 7% in US dollars but were up 1% in local currencies as strong performances from Diovan/Co-Diovan, Gleevec/Glivec, Femara, Comtan/Stalevo and ... - Houston Chronicle





AAN: New Parkinson's Disease Treatment Guidelines Issued  Apr 7, 2006
The guidelines included the use of new drugs, Comtan (entacapone) and Azilect (rasagiline), and indicated that there is a role in treatment for deep brain ... - MedPage Today

New Guidelines Update Diagnosis and Treatment of Parkinson's ...  Apr 4, 2006
Rajesh Pahwa, MD, noted that there is strong evidence supporting the use of entacapone (Comtan) and rasagiline (Azilect) to reduce "off" time in patients whose ... - Medscape (subscription)

New laboratory approach to treat Parkinson’s  Mar 27, 2006
...the brain. Comtan (entacapone), a so-called COMT inhibitor, has the same effect as carbidopa when taken along with levodopa. It ... - LabTechnologist.com

Orion Oyj: Orion group 2005 financial statements  09 Feb 2006
The proprietary products for Parkinson’s Disease, Stalevo® and Comtess®/Comtan®, contributed EUR 145.3 (115.6) million, or 27% (22%) of the total net ... - Kauppalehti

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional